Screening of the founder pathogenic variants BRCA1 and BRCA2 in Russian metropolitan women Authors: Natalia Bodunova, Airat Bilyalov, Anastasiia Danishevich, Gurami Kvetenadze, Artem Andronov, Andrey Starshinin, Konstantin Rumyantsev, Ludmila Zhukova, Alexey Khripun, Igor Khatkov Published: 2025 ABSTRACT BackgroundHereditary cancer and associated high risk genetic variants accountable for 5–10% of all breast cancer cases carry a significant burden on the health system and the pathogenic variants carriers. The harm from these factors can be significantly reduced through the timely detection of genetic alterations and implementation of health monitoring programs for pathogenic variants carriers.MethodsWe conducted a population-based genetic screening of unselected women residing in a large metropolitan area in 2018. Testing targeted eight recurrent BRCA1/2 founder pathogenic variants using validated real-time PCR assays. Women with a detected variant were invited into a structured prospective surveillance program with standardized capture of clinical outcomes. The primary outcome was the prevalence of BRCA1/2 founder variants; secondary outcomes included age and family-history profiles, adherence to surveillance, and cancer incidence and stage among carriers. Analyses used descriptive summaries, χ² or Fisher’s exact tests for proportions, Mann–Whitney tests for continuous variables, and risk ratios with 95% confidence intervals.ResultsThe study included a large cohort of 107,300 women. 402 identified pathogenic variant carriers were offered consultations by a geneticist and regular health monitoring, 94.3% of them agreed to participate and made a median of two visits. Among 402 identified BRCA1/2 pathogenic variant carriers, 386 women (0.36%) had pathogenic variants in the BRCA1 gene and 16 women (0.01%) had pathogenic variants in the BRCA2 gene. The BRCA1 variant c.5266dup accounted for 66.2% of all pathogenic variant detected. BRCA1/2 pathogenic variants were significantly associated with a high incidence of cancer in both pathogenic variants carriers and their relatives. Only 27.2% of pathogenic variants carriers met clinical guidelines for genetic screening, while 6.3% of women without detected pathogenic variants were eligible for genetic testing. Through a follow-up medical surveillance program, the percentage of cancers detected at an early stage in pathogenic variants carriers increased from 65% to 93%.ConclusionsThe findings of this study highlight the critical need for improved genetic screening protocols to identify high-risk individuals effectively. By refining clinical guidelines and implementing comprehensive follow-up programs, healthcare systems can enhance early detection rates of cancers associated with BRCA1/2 variants, ultimately leading to better patient outcomes and personalized healthcare strategies.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12905-025-04164-6. Background Screening for genetically determined diseases is the basis of future personalized health care. As is known, about 10% of breast cancer and 20% of ovarian cancer are a con-sequence of the carriage germline pathogenic variants in cancer-predisposition genes; tumorigenesis arises after additional somatic events [1]. The BRCA1/2 genes are the most studied hereditary cancer genes [1, 2]. Pathogenic/likely pathogenic variants in BRCA1/2 confer high lifetime risks of breast cancer (≈ 70%) and ovarian cancer (≈ 44% for BRCA1; ≈17% for BRCA2) by age 80 [3, 4]. Genetic testing for pathogenic variants in BRCA1/2 genes holds significant relevance in informing risk-reducing strategies for unaffected individuals at increased hereditary risk and guiding treatment decisions for affected patients [5]. The presence of BRCA1/2 variants is also associated with an increased risk of developing pancreatic and stomach cancers, in addition to breast cancer in both women and men, as well as prostate cancer in men [5–9]. Currently, the first step during the molecular genetic diagnostics of hereditary breast and ovarian cancer in Russia is application of founder pathogenic variants BRCA1 (с.5266dup, с.181T >G, с.1961del, с.4035del, с.68_69delAG, с.3756_3759del, с.3700_3704del) and BRCA2 (c.5946del) by PCR-panel. “In our region, a small set of recurrent BRCA1/2 founder pathogenic variants accounts for a substantial fraction of hereditary cases, supporting a founder-panel as a pragmatic first-line test; comprehensive NGS can follow unresolved cases [10–12]. We used a limited BRCA1/2 founder-variant panel as a pragmatic first-line test to maximize diagnostic yield at minimal cost under real-world conditions. In our population, a small set of recurrent, well-validated variants accounts for a substantial fraction of hereditary cases; unresolved cases proceed to comprehensive NGS [13]. Thus, our study aimed to estimate the frequency of founder BRCA1/2 pathogenic variants in a metropolitan population of women and to evaluate the clinical value of preventive examinations for detecting malignancies in BRCA1/2 pathogenic variants carriers. Methods Study design and recruitment An overview of the study design is provided in Fig. 1. The Loginov Moscow Clinical Scientific Center (MCSC) local ethical committee and Academic Council reviewed and approved the study design and informed consent form at the meetings on February 14 and 16, 2018, respectively (protocol #12044). Information about the study was disseminated through the mass media (local newspapers and television), the website of the Moscow Department of Health (mosgorzdrav.ru), and word of mouth. All participants were unselected women aged ≥ 18 years from Moscow, recruited via a city-wide media invitation, no additional selection criteria were applied, aiming to obtain a broadly representative metropolitan sample. Informed consent to participate was obtained from all of the participants in written form. The study recruited 107300 participants from several outpatient hospitals of the Moscow Health Department in Moscow, Russian Federation. A peripheral blood sample was taken after the participant signed an informed consent form and filled out a short questionnaire with information about the personal and family medical history. The participants were informed about the results of the genetic test by email or through their attending physician at a local clinic within 7–14 business days. The pilot phase of the study took place on March 17 and 18, 2018, with additional recruitment taking place from June 7 to September 30, 2018. Fig. 1Overview of the study design Overview of the study design Questionnaire for participants The questionnaire for collecting captured personal medical history of malignant neoplasms (breast cancer, ovarian cancer, pancreatic cancer, other malignancies) and selected benign conditions (ovarian cysts, fibrocystic breast disease, benign breast neoplasms) colorectal cancer. For family history (first- and second-degree relatives), the questionnaire listed breast cancer, ovarian cancer, pancreatic cancer, prostate cancer, and other malignancies. Participants were also asked to add information about any other medical conditions in their personal or their family’s medical history. To ensure terminological consistency, ‘ovarian cancer’ and ‘malignant neoplasm of the ovary’ were treated as synonyms; throughout the manuscript we uniformly use ‘ovarian cancer (OC)’. Benign conditions (e.g., ovarian cysts) were not counted as cancer outcomes. If both options were selected by a participant due to interface wording, records were deduplicated to a single ‘ovarian cancer’ entry. After completion, questionnaires remained at the local outpatient hospital and 11079 randomly selected questionnaires were scanned and digitized to be converted into a digital database. Genetic testing Genomic DNA was extracted from peripheral whole blood samples using the RealBest UniMag DNA extraction kit (AO Vector-Best, Russia) for the KingFisher Flex system (Thermo Fisher, USA). Eight recurrent BRCA1/2 founder pathogenic variants (Table 1) were assayed using four RealBest-Genetics BRCA real-time PCR kits (AO Vector-Best, Russia; Cat. № 3807, 3808, 3809, 3841), per the manufacturer’s instructions. Collectively, these kits target BRCA1 c.68_69delAG (185delAG), c.181T > G (p.Cys61Gly), c.1961del (2080delA), c.3700_3704del (3819del5), c.3756_3759del (3875del4), c.4035delA (4153delA), c.5266dupC (5382insC), and BRCA2 c.5946delT (6174delT); HGVS/rsIDs are provided in Table 1. Table 1BRCA1/2 founder pathogenic variants and their minor allele frequencyGeneGenomic location (GRCh38)HGVS codingrsIDProteinThis studyGnom AD v2.1.1*Gnom AD v3.1.2* BRCA1 17:43057062NM_007294.4:c.5266dup (5382insC)rs80357906p.(Gln1756fs)1.24*10− 31.94*10− 45.88*10− 5 BRCA1 17:43106487NM_007294.4:c.181T > G (300T > G)rs28897672p.(Cys61Gly)1.63*10− 46.17*10− 57.35*10− 5 BRCA1 17-43093570NM_007294.4:c.1961del (2080delA)rs80357522p.(Lys654fs)1.35*10− 42.33*10− 51.47*10− 5 BRCA1 17-43091496NM_007294.4:c.4035del (4153delA)rs80357711p.(Glu1346fs)1.26*10− 49.30*10− 58.82*10− 5 BRCA1 17-43124027NM_007294.4:c.68_69del (185delAG)rs80357914p.(Glu23fs)7.46*10− 58.54*10− 52.94*10− 5 BRCA1 17:43091771NM_007294.4:c.3756_3759del (3875del4)rs80357868p.(Ser1253fs)3.26*10− 54.40*10− 52.94*10− 5 BRCA1 17:43091827–43,091,831NM_007294.4:c.3700_3704del (3819del5)rs80357609p.(Val1234fs)2.80*10− 5–– BRCA2 13:32340300NM_000059.4:c.5946del (6174delT)rs80359550p.(Ser1982fs)7.46*10− 51.09*10− 48.82*10− 5* Genome Aggregation Database (gnomAD), European (Non-Finnish) Table 1BRCA1/2 founder pathogenic variants and their minor allele frequencyGeneGenomic location (GRCh38)HGVS codingrsIDProteinThis studyGnom AD v2.1.1*Gnom AD v3.1.2* BRCA1 17:43057062NM_007294.4:c.5266dup (5382insC)rs80357906p.(Gln1756fs)1.24*10− 31.94*10− 45.88*10− 5 BRCA1 17:43106487NM_007294.4:c.181T > G (300T > G)rs28897672p.(Cys61Gly)1.63*10− 46.17*10− 57.35*10− 5 BRCA1 17-43093570NM_007294.4:c.1961del (2080delA)rs80357522p.(Lys654fs)1.35*10− 42.33*10− 51.47*10− 5 BRCA1 17-43091496NM_007294.4:c.4035del (4153delA)rs80357711p.(Glu1346fs)1.26*10− 49.30*10− 58.82*10− 5 BRCA1 17-43124027NM_007294.4:c.68_69del (185delAG)rs80357914p.(Glu23fs)7.46*10− 58.54*10− 52.94*10− 5 BRCA1 17:43091771NM_007294.4:c.3756_3759del (3875del4)rs80357868p.(Ser1253fs)3.26*10− 54.40*10− 52.94*10− 5 BRCA1 17:43091827–43,091,831NM_007294.4:c.3700_3704del (3819del5)rs80357609p.(Val1234fs)2.80*10− 5–– BRCA2 13:32340300NM_000059.4:c.5946del (6174delT)rs80359550p.(Ser1982fs)7.46*10− 51.09*10− 48.82*10− 5* Genome Aggregation Database (gnomAD), European (Non-Finnish) BRCA1/2 founder pathogenic variants and their minor allele frequency * Genome Aggregation Database (gnomAD), European (Non-Finnish) Follow-up monitoring All women received the result of the study in the way they chose, regardless of whether it was positive or negative. A geneticist contacted women with a positive genetic test by telephone and invited them to undergo an additional free examination to identify existing pathology and receive post-test genetic counseling. The initial examination according to international recommendations for BRCA1/2 pathogenic variants carriers consisted of collecting medical history, ultrasound of the small pelvis and mammary glands, mammography, and mammologist’s consultation [14–16]. During the genetic counseling session, women were invited for a follow-up examination, scheduled every 6–12 months, depending on the results of previous examinations. Statistical analysis Participant characteristics, genetic testing results, and questionnaire data were tabulated with descriptive statistics including median and interquartile range or means and standard deviations for continuous data; proportions with 95% confidence intervals for categorical data. The statistical analysis was carried out using GraphPad Prism v. 10.0.0 (GraphPad Software, USA). Statistical significance was evaluated for the association between the categorical variables using the Chi‑ square test, Fisher’s exact test, and Mann–Whitney U-test. The statistical test was selected based on the sample size and the magnitude of the effect in the compared patient groups. All P values are two-tailed and P < 0.05 was considered statistically significant. Results A total of 107300 women took part in the study. According to a random sample from the questionnaires of the study participants (n = 11 079), their ages ranged from 18 to 94 years. This systematic random sampling was performed using R statistical software (version 4.0.2), with a fixed random seed (set to 123) to ensure reproducibility. The median age (inter-quartile range) among these individuals at the time of genetic testing was 54.3 (41.4–64.7) years. Out of 107300 women, 386 (0.36%) had pathogenic variants in the BRCA1 gene and 16 (0.01%) in the BRCA2 gene. The allelic frequency of founder BRCA1/2 pathogenic variants was 1.87*10− 3. Upon receiving positive test results, out of 402 women, only 11 (2.7%) of them independently sought counseling. To explain the significance of the identified pathogenic variant and to attract more participants to the observation program, we contacted participants by phone. As a result, an additional 318 women agreed to genetic counseling and participation in a follow-up monitoring program. Thus, 329 BRCA1/2 pathogenic variants women (consent rate of 81.8%) continued to participate in the study, attended an appointment with a geneticist, shared their personal and family medical history, and underwent an examination of the breasts and pelvic organs. Over the next three and a half years, 329 participants in the monitoring program made 982 visits including the first one (Fig. 2). 54 women did not return after the initial examination without explicit refusal to participate. 160 women completed at least three examinations during this period. On average, women in the monitoring program visited the clinic 2.8 ± 1.9 times, which is less than half of the 7 recommended visits in the three and a half year period. Fig. 2Distribution of participants by number of completed follow-up visits in the surveillance cohort (n = 329). Y-axis shows % of the cohort; “0” = consented but no post-baseline visit. Total visits 982 (mean 2.8 ± 1.9); median follow-up ≈ 3.5 years Distribution of participants by number of completed follow-up visits in the surveillance cohort (n = 329). Y-axis shows % of the cohort; “0” = consented but no post-baseline visit. Total visits 982 (mean 2.8 ± 1.9); median follow-up ≈ 3.5 years Among pathogenic variants women, there were members of 12 families; most were either mother and daughter or two sisters. Based on counseling and clinical examination data from women carrying BRCA1/2 pathogenic variants, we compiled a per-variant summary—including the number of women identified with each variant (n) and their clinical histories—in Supplementary Table S1.We did not find statistically significant differences in obstetric history between carriers of BRCA1 and BRCA2 pathogenic variants, however, a relatively large percentage of women have had abortions (48.5%) and miscarriages (13.5%) in comparison with national averages [17]. Even though the proportion of cases of breast cancer in those who gave birth (16.1%) was less than in those who did not (19.7%), the difference was not statistically significant (p = 0.46, χ2). In the medical history, we found statistically significant differences between the groups of BRCA1 pathogenic variants carriers and BRCA2 pathogenic variant carriers in the number of women with fibrocystic breast disease (p = 0.0012, χ2), women who had a mastectomy (p = 0.0182, χ2), and women with bilateral breast cancer (p < 0.0001, χ2). Important to note that a modified radical mastectomy was a part of the breast cancer treatment and none of the women had the opportunity to have a prophylactic mastectomy due to legal restrictions [18]. Similarly, risk-reducing salpingo-oophorectomy is not legally permissible in Russia [19]. These legal constraints limit risk-reducing surgical options and may diminish the overall effectiveness of preventive strategies. We used the cases of BRCA1/2 pathogenic variants women with cancer from the follow-up cohort and of BRCA1/2 variant-negative women obtained from the random sample from the screening participants’ questionnaires to estimate the number of cancer cases in each group and the age of onset of some cancer types (Table 2). The mean age at breast cancer diagnosis was significantly lower in variant-positive than in variant-negative women (46.8 ± 11.9 vs. 52.9 ± 13.0 years; p = 0.026, Mann–Whitney U test). No significant differences were observed for age at diagnosis of any cancer (49.1 ± 13.3 vs. 51.3 ± 14.1 years), ovarian cancer (50.2 ± 12.6 vs. 45.2 ± 14.1 years), or uterine cancer (47.9 ± 13.6 vs. 54.2 ± 9.5 years). However, differences in incidence among women with and without identified germline pathogenic variants were significant for most types of cancer, except for colon, pancreas, esophagus, and stomach cancers. The analysis of the relative risks of cancer between the groups showed a significant increase in risk for all types of cancer among BRCA1/2 pathogenic variant carriers. The risk of second cancer, bilateral breast cancer, or thyroid cancer was especially high. Table 2Cancer cases in BRCA1/2 variant positive and variant-negative womenCancer typeVariant-positive (n = 379)Variant-negative (n = 11079)RR(CI 95%)P, χ2 n % n %Any cancer9324.543232.928.42(6.82–10.31) < 0.0001 1 primary cancer6918.213092.796.53(5.12–8.26) < 0.0001 2 primary cancers236.07140.1348.02(25.15–91.42) < 0.0001 ≥ 3 primary cancers10.2600.0– – Breast cancer6316.621461.3212.68(9.59–16.66) < 0.0001 of them bilateral123.1720.02175.4(44.05–697.7) < 0.0001 of them in women ≤ 50 yo379.76510.4621.21(14.07–31.8) < 0.0001 Ovarian cancer236.071161.055.8(3.75–8.89) < 0.0001 Uterine cancer112.90100.0932.16(14.04–73.35) < 0.0001 Melanoma30.7930.0329.23(6.76–126.1) < 0.0001 Thyroid cancer30.7910.0187.7(12.58–610.8) < 0.0001 Colorectal cancer20.53450.411.29 (0.35–4.81)0.7159Urinary tract and bladder cancer10.2620.0214.62(1.92–111.2) 0.0036 Esophageal carcinoma10.2600.0––Pancreatic cancer00.080.07–0.6008Stomach cancer00.010.01–0.8533The bold font indicates statistically significant results Table 2Cancer cases in BRCA1/2 variant positive and variant-negative womenCancer typeVariant-positive (n = 379)Variant-negative (n = 11079)RR(CI 95%)P, χ2 n % n %Any cancer9324.543232.928.42(6.82–10.31) < 0.0001 1 primary cancer6918.213092.796.53(5.12–8.26) < 0.0001 2 primary cancers236.07140.1348.02(25.15–91.42) < 0.0001 ≥ 3 primary cancers10.2600.0– – Breast cancer6316.621461.3212.68(9.59–16.66) < 0.0001 of them bilateral123.1720.02175.4(44.05–697.7) < 0.0001 of them in women ≤ 50 yo379.76510.4621.21(14.07–31.8) < 0.0001 Ovarian cancer236.071161.055.8(3.75–8.89) < 0.0001 Uterine cancer112.90100.0932.16(14.04–73.35) < 0.0001 Melanoma30.7930.0329.23(6.76–126.1) < 0.0001 Thyroid cancer30.7910.0187.7(12.58–610.8) < 0.0001 Colorectal cancer20.53450.411.29 (0.35–4.81)0.7159Urinary tract and bladder cancer10.2620.0214.62(1.92–111.2) 0.0036 Esophageal carcinoma10.2600.0––Pancreatic cancer00.080.07–0.6008Stomach cancer00.010.01–0.8533The bold font indicates statistically significant results Cancer cases in BRCA1/2 variant positive and variant-negative women 8.42 (6.82–10.31) 6.53 (5.12–8.26) 48.02 (25.15–91.42) 12.68 (9.59–16.66) 175.4 (44.05–697.7) 21.21 (14.07–31.8) 5.8 (3.75–8.89) 32.16 (14.04–73.35) 29.23 (6.76–126.1) 87.7 (12.58–610.8) 14.62 (1.92–111.2) The bold font indicates statistically significant results Concerning family cancer history, we also compared the burden between variant-positive and variant-negative women (Table 3). The collected data demonstrated that only 26.4% of pathogenic variant carriers had an unburdened oncological history, while the majority 70.6% of women without pathogenic variants did not report having any relatives with cancer. The largest difference was observed primarily for relatives affected by breast cancer, reaching 3,5 times more breast cancer cases in relatives of pathogenic variants women. The proportion of relatives who developed breast cancer before age 50, which may indicate the hereditary nature of cancer, was also more than twice as high among relatives of pathogenic variants women. Relatives affected with ovarian cancer were also more prevalent among women with pathogenic variants. In addition, we did not find significant differences in the number of relatives affected by cancer of the pancreas, colon, gallbladder, or esophagus. Table 3Family cancer history in BRCA1/2 variant-positive and variant-negative womenFamily history in first-/second-degree relatives: number of affected relatives per participant, age at diagnosis ≤ 50 years, and male relatives (where applicable)Variant-positive women (n = 353) Variant-negative women (n = 11079) P, χ2 n % n %Any cancer26073.65325729.40 < 0.0001 1 affected relative11332.01254322.95 0.0001 2 affected relative9426.635715.15 < 0.0001 3 affected relative4512.751080.97 < 0.0001 4 affected relative51.42250.23 < 0.0001 ≥ 5 affected relative30.85100.09 < 0.0001 Breast cancer15142.78135212.20 < 0.0001 1 affected relative11231.73126211.39 < 0.0001 2 affected relative339.35870.79 < 0.0001 ≥ 3 affected relative61.7030.03 < 0.0001 relatives diagnosed ≤ 50 years348.504754.29 < 0.0001 male relatives19.6310.01 0.0001 Ovarian cancer580.284924.44 < 0.0001 1 affected relative4816.434814.34 < 0.0001 2 affected relative1013.60110.10 < 0.0001 Prostate cancer192.833353.02 0.0192 Pancreatic cancer165.384824.350.9048Stomach cancer344.53860.78 < 0.0001 Colorectal cancer209.639278.370.0621Melanoma95.6780.07 < 0.0001 Gallbladder cancer02.5530.030.7558Uterine cancer260.00300.27 < 0.0001 Lung cancer177.37380.34 < 0.0001 Head and neck tumors74.82180.16 < 0.0001 Leukemia91.98100.09 < 0.0001 Malignant brain tumor62.5570.06 < 0.0001 Urinary tract and bladder cancer71.70120.11 < 0.0001 Hepatic cancer41.9880.07 < 0.0001 Thyroid cancer41.1330.03 < 0.0001 Esophageal carcinoma31.13160.140.0015Unspecified cancer310.85120.11 < 0.0001 The bold font indicates statistically significant results Table 3Family cancer history in BRCA1/2 variant-positive and variant-negative womenFamily history in first-/second-degree relatives: number of affected relatives per participant, age at diagnosis ≤ 50 years, and male relatives (where applicable)Variant-positive women (n = 353) Variant-negative women (n = 11079) P, χ2 n % n %Any cancer26073.65325729.40 < 0.0001 1 affected relative11332.01254322.95 0.0001 2 affected relative9426.635715.15 < 0.0001 3 affected relative4512.751080.97 < 0.0001 4 affected relative51.42250.23 < 0.0001 ≥ 5 affected relative30.85100.09 < 0.0001 Breast cancer15142.78135212.20 < 0.0001 1 affected relative11231.73126211.39 < 0.0001 2 affected relative339.35870.79 < 0.0001 ≥ 3 affected relative61.7030.03 < 0.0001 relatives diagnosed ≤ 50 years348.504754.29 < 0.0001 male relatives19.6310.01 0.0001 Ovarian cancer580.284924.44 < 0.0001 1 affected relative4816.434814.34 < 0.0001 2 affected relative1013.60110.10 < 0.0001 Prostate cancer192.833353.02 0.0192 Pancreatic cancer165.384824.350.9048Stomach cancer344.53860.78 < 0.0001 Colorectal cancer209.639278.370.0621Melanoma95.6780.07 < 0.0001 Gallbladder cancer02.5530.030.7558Uterine cancer260.00300.27 < 0.0001 Lung cancer177.37380.34 < 0.0001 Head and neck tumors74.82180.16 < 0.0001 Leukemia91.98100.09 < 0.0001 Malignant brain tumor62.5570.06 < 0.0001 Urinary tract and bladder cancer71.70120.11 < 0.0001 Hepatic cancer41.9880.07 < 0.0001 Thyroid cancer41.1330.03 < 0.0001 Esophageal carcinoma31.13160.140.0015Unspecified cancer310.85120.11 < 0.0001 The bold font indicates statistically significant results Family cancer history in BRCA1/2 variant-positive and variant-negative women The bold font indicates statistically significant results Having at our disposal data on cancer incidence in women who participated in genetic screening and their relatives, we decided to assess the risk of carrying pathogenic variants and the need for genetic testing in them according to the criteria of the National Comprehensive Cancer Network (NCCN) guidelines. By applying these regularly updated criteria (Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, version 3.2024) we were able to divide our cohort into several groups according to the assessed risk of hereditary cancer: (1) those who would be eligible for genetic testing and (2) those for whom it was not necessary according to the guidelines (Supplementary table S2). Among women with identified pathogenic variants, we determined that only 27.18% of them met the NCCN criteria before they participated in the screening and found out their genetic status. Our cohort’s broadest criterion for genetic testing eligibility was having ovarian cancer or relatives with this diagnosis. In addition, the next most important NCCN criterion was having breast cancer with onset before age 45 for pathogenic variants women or a relative with breast cancer for variant-negative women. The remaining criteria contribute less to the number of women who would have been recommended to consider genetic testing for hereditary cancer syndrome before this screening. The combination of the medical history and observation data of the 379 follow-up program participants made it possible to compare the number of cases of cancer, the age of onset, and the stage at the time of diagnosis before and after women underwent genetic testing. According to the collected medical history, at the time of genetic testing, 64 women (16.4%) had either breast, ovarian, thyroid, skin, kidney, or colorectal cancer. The stage of the disease at the time of initial diagnosis was known in 55 women (Table 4). At the initial examination of the follow-up monitoring, malignant neoplasms were detected in 8 women. Of the 31 cancer cases detected in 29 women, 14 were diagnosed in women under 50. Before the genetic testing, only 65% of cancers were detected at early stages (0, I, or II), while after the testing, regular participation in the monitoring program increased this figure to 93.5%. Table 4Cancer diagnostics in participants before or after the BRCA1/2 genetic screening. (n = 379)Cancer typeNo. of casesIn situIIIIIIIV Before screening Breast cancer*37072352 Ovarian cancer1100092 Uterine cancer604110 Skin cancer101000 Sum5501224154Cancers detected before the screening (%)021.8243.6427.277.27 After screening Breast cancer**262121110 Ovarian cancer200110 Uterine cancer101000 Kidney cancer101000 Skin cancer101000 Sum312151220Cancers detected after the screening (%)6.4548.3938.716.450* 10 women had bilateral cancer (7 – BRCA1 5266dup; 3 – BRCA2)** 2 women had bilateral cancer (1 – BRCA1 5266dup; 1 – BRCA2) Table 4Cancer diagnostics in participants before or after the BRCA1/2 genetic screening. (n = 379)Cancer typeNo. of casesIn situIIIIIIIV Before screening Breast cancer*37072352 Ovarian cancer1100092 Uterine cancer604110 Skin cancer101000 Sum5501224154Cancers detected before the screening (%)021.8243.6427.277.27 After screening Breast cancer**262121110 Ovarian cancer200110 Uterine cancer101000 Kidney cancer101000 Skin cancer101000 Sum312151220Cancers detected after the screening (%)6.4548.3938.716.450* 10 women had bilateral cancer (7 – BRCA1 5266dup; 3 – BRCA2)** 2 women had bilateral cancer (1 – BRCA1 5266dup; 1 – BRCA2) Cancer diagnostics in participants before or after the BRCA1/2 genetic screening. (n = 379) * 10 women had bilateral cancer (7 – BRCA1 5266dup; 3 – BRCA2) ** 2 women had bilateral cancer (1 – BRCA1 5266dup; 1 – BRCA2) Discussion In this study, we identified women who met the NCCN criteria for genetic testing as potential candidates for a broader genetic panel based on their family and/or personal history. However, due to budgetary constraints and the focus on cost-effectiveness, we prioritized screening for the most common BRCA1/2 founder pathogenic variants prevalent in the population. This strategic decision allowed us to maximize the study’s reach and impact within the available resources, while still providing valuable insights into hereditary cancer risk. As a result, we found 0.37%-unselected probands have a founder pathogenic variant in the BRCA1/2 gene. According to early data, the BRCA1/2 pathogenic variants frequency in the general population is 1:300–800, among Ashkenazi Jews they are detected more often – 1:40 [20, 21]. In Russian patients with breast cancer the incidence of pathogenic variants in the BRCA1/2 genes in ranges from 0.1 to 25.6% (BRCA1–0.1-25.6%; BRCA2–0.1-0.5%), in patients with ovarian cancer - from 0.3 to 35% (BRCA1–10.29- 27%; BRCA2–0.3-8%) [22]. The variant с.5266dup is predominant and is found in 57–68%, the c.4153del pathogenic variant ranks second - in 12.5% of all BRCA-associated breast cancer cases [10]. A comparison of allele frequencies in our study and the Genome Aggregation Database (gnomAD) showed that four pathogenic variants were more frequent (BRCA1 с.5266dup, с.181T >G, с.1961del, с.4035del) and one of the pathogenic variants was less frequent (BRCA2 c.5946del) than was shown previously for the European (non-Finnish) population. Notably, the BRCA2 c.5946del pathogenic variant identified in our study is exclusively associated with Jewish Ashkenazi ancestry and has never been reported in non-Ashkenazi Jewish populations [23]. Similarly, the BRCA1 c.185delAG pathogenic variant we detected has a strong predominance in Jewish populations, particularly among those of Ashkenazi descent [24]. These findings suggest a possible Ashkenazi Jewish genetic component in our study population Since the allelic frequency of BRCA1 с.3700_3704del was not present in the gnomAD, for comparison we used a study of BRCA1 pathogenic variant frequency in the Polish population [25]. In this study, BRCA1 c.3700_3704del frequency (5.10*10− 4) was 9.12 times higher than in our study. Pregnancy-associated breast cancer (PABC)—defined as breast cancer diagnosed during pregnancy or within 12 months postpartum—appears relatively rare among BRCA1/2 carriers but more frequent than in the general population. Renata Faermann et al. reported an overall PABC incidence of 2.05% among BRCA1/2 carriers, higher than in the general population [26]. Our study was not powered to estimate PABC incidence; we therefore reference this risk for context and do not derive inferences from our data. Reproductive-history variables relate to lifetime risk and are distinct from the PABC entity. In our cohort, parity per se was not associated with breast cancer among carriers (parous vs. nulliparous: χ², p = 0.46). Reported rates of induced abortions and miscarriages were 48.5% and 13.5%, respectively; we present these descriptively and do not interpret them as protective or causal. These data are elaborated in the following paragraph on reproductive modifiers of risk. We did not find statistically significant differences in obstetric history between carriers of BRCA1 and BRCA2 pathogenic variants. The relationship between BRCA1/2 mutations and miscarriage rates remains a topic of ongoing debate in the literature. While Kwiatkowski et al. reported that BRCA1/2 carriers experienced 36% fewer miscarriages compared to non-carriers, this assertion is not universally supported [27]. For instance, Dellino et al. found no significant difference in miscarriage rates between women with BRCA1/2 germline mutations and those without, suggesting that the reproductive outcomes for these populations may be more complex than previously thought [28] Furthermore, Gal et al. reported elevated rates of recurrent miscarriages in a specific cohort of Jewish women at high risk for breast and ovarian cancer, indicating that genetic predispositions may interact with other factors to influence reproductive outcomes [29]. The largest difference was observed for relatives affected by breast cancer - up to 3.5 times more breast cancer cases in relatives of pathogenic variants women. The proportion of relatives who developed breast cancer before age 50, was found to be more than twice as high among relatives of female pathogenic variant carriers which may indicate the hereditary nature of cancer. Another study has shown, that the incidences of breast cancer in female relatives of BRCA1 carriers, BRCA2 carriers, and non-carriers were 33.0%, 32.2%, and 7.7%, respectively and the corresponding incidences of ovarian cancer were 11.5%, 2.4%, and 0.5%, respectively. The risks of breast and ovarian cancers in female relatives of BRCA1 and BRCA2 carriers were found to be significantly higher than in female relatives of non-carriers (BRCA1: RR = 4.29, P < 0.001 and RR = 21.95, P < 0.001; BRCA2: RR = 4.19, P < 0.001 and RR = 4.65, P < 0.001, respectively). Liu J et al. have also reported higher risks of pancreatic and prostate cancers in male relatives of BRCA2 carriers than non-carriers (RR = 4.34, P = 0.001 and RR = 4.86, P = 0.001, respectively) [30]. We have achieved a significant increase in the early detection rate of cancer in BRCA1/2 pathogenic variant carriers. Before genetic testing, only 65% of cancers were detected at early stages (0, I, or II), but after testing, regular participation in a monitoring program increased this figure to 93.5%. This indicates the high effectiveness of screening. Like other researchers, we also detected breast cancer more often in pathogenic variant carriers (23.9%; 96/402). We found a significant difference between variant-positive and variant-negative women in the age of onset of only breast cancer − 46.8 ± 11.9 vs. 52.9 ± 13.0 (p = 0.02642). These findings go along with the results of similar studies [31]. The risk of second breast cancer was especially high, bilateral breast cancer was detected in women with BRCA1 pathogenic variant only. Similar results were obtained by Tehillah S. et al. the cumulative incidence of second primary breast cancer was found to be higher in BRCA1 pathogenic variant carriers, in comparison to BRCA2 pathogenic variant carriers – the overall 10-year probability of 17% vs. 7% (p < 0.001) [32]. Study limitations While this study provides valuable insights into genetic screening of the founder variant BRCA1/BRCA2in a cohort of Russian women, certain limitations should be acknowledged. The recruitment strategy, which involved local media advertisements, may have led to a sample with a heightened awareness of cancer risk, potentially influencing participation rates. However, this approach also ensured a diverse and engaged cohort. The reliance on self-reported medical history, while common in large-scale studies, may introduce some inaccuracies, yet it provides a practical means of gathering extensive data. The information provided in result reports was designed to be clear and actionable, though future iterations could enhance detail to further support participant understanding. Lastly, while a decline in screening attendance over time was observed, the initial high engagement levels underscore the program’s potential impact. These considerations highlight areas for future refinement while affirming the study’s contributions to personalized cancer prevention strategies. Conclusions For the first time in Russia, we conducted a large population-based study involving 107300 unselected women to identify common pathogenic variants in the BRCA1/2 genes. The database of 402 BRCA1/2 pathogenic variant carriers was created, and 81.8% of these women continued to participate in the study and were screened at least once. This made it possible to increase the detection of cancer in the early stages in this patient from 65% to 93.5%. The findings of our study emphasize the critical role of genetics in personalized breast cancer screening. By incorporating genetic risk assessment into screening protocols, we can potentially delay mammography for women at low risk, in line with recent recommendations to reduce over screening and associated costs [33]. We concluded that maintaining regular contact between the medical organization and the patient increases the compliance of pathogenic variant carriers. This significantly increases the efficiency of screening and early cancer detection in BRCA1/2 pathogenic variant carriers. Supplementary Information Supplementary Material 1: Table S1. Medical history and examination results of BRCA1/2 pathogenic variants women. Supplementary Material 1: Table S1. Medical history and examination results of BRCA1/2 pathogenic variants women. Supplementary Material 2: Table S2. Segregation of study participants according to NCCN guidelines for genetic risk evaluation at the time of genetic screening. Supplementary Material 2: Table S2. Segregation of study participants according to NCCN guidelines for genetic risk evaluation at the time of genetic screening.